Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NATIONAL PATENT JOINT VENTURE AIDS COMPOUND CLINICAL TRIALS

Executive Summary

NATIONAL PATENT JOINT VENTURE AIDS COMPOUND CLINICAL TRIALS will begin in the next four to six weeks, the company announced June 29. "Pursuant to an IND application filed with the FDA, the study, which is expected to commence in four to six seeks, is designed to test the effects of AS101 on approximately 30 AIDS patients," the release states. Scientific Testing Inc., a joint venture between National Patent Development and Bar Ilan University of Isreal, is the drug's sponsor. A proprietary synthetic compound, AS101 "has shown immuno-augmenting, antiviral and antitumor activity in preclinical animal testing and immuno-augmenting activity in a limited number of AIDS patients in Phase I foreign clinical tests," according to the release. "The clinical study will be conducted at the Institute for Immunological Disorders (M.D. Anderson Hospital) Houston, Texas, under the direction of Dr. Peter Mansell," the release notes. Previously, Mansell directed a trial of ICN's Virazole (ribavirin) in AIDS patients at that center. Other preliminary foreign trials testing AS101 against various cancers are either under development or have been started, National Patent added.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012131

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel